Wasatch Advisors Inc C4 Therapeutics, Inc. Transaction History
Wasatch Advisors Inc
- $20.1 Billion
- Q3 2024
A detailed history of Wasatch Advisors Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Wasatch Advisors Inc holds 5,677,368 shares of CCCC stock, worth $24.4 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
5,677,368
Previous 4,847,150
17.13%
Holding current value
$24.4 Million
Previous $22.4 Million
44.51%
% of portfolio
0.16%
Previous 0.12%
Shares
15 transactions
Others Institutions Holding CCCC
# of Institutions
130Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Lynx1 Capital Management LP San Juan, PR6.88MShares$29.6 Million14.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$28.4 Million3.2% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$21 Million0.39% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$19.6 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.38MShares$18.8 Million0.59% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $210M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...